- Home
- CYH vs CRMD Comparison
CYH vs CRMD Comparison
Compare CYH & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYH | CRMD |
|---|---|---|
| Founded | 1985 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.2M | 626.0M |
| IPO Year | 2000 | 2009 |
Fundamental Metrics
Financial Performance| Metric | CYH | CRMD |
|---|---|---|
| Price | $2.82 | $8.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $3.28 | ★ $14.83 |
| AVG Volume (30 Days) | 1.3M | ★ 1.3M |
| Earning Date | 04-21-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 196.67 | ★ 780.00 |
| EPS | N/A | ★ 0.43 |
| Revenue | ★ $12,485,000,000.00 | $311,709,000.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | $2.17 | N/A |
| P/E Ratio | ★ N/A | $19.59 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $2.39 | $6.13 |
| 52 Week High | $4.43 | $17.43 |
Technical Indicators
Market Signals| Indicator | CYH | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 46.95 | 62.44 |
| Support Level | $2.71 | $6.14 |
| Resistance Level | $3.00 | $8.53 |
| Average True Range (ATR) | 0.11 | 0.38 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 39.34 | 65.23 |
Price Performance
Historical ComparisonAbout CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.